Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00551512 · ClinicalTrials.gov registry record · Phase 1

Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors

A Phase 1 study of Cancer and Solid Tumors, sponsored by CanBas Co..

Completed
Registry status
Phase 1
Development phase
48
Enrollment target
3
Study locations

NCT00551512 is a Phase 1 study of Cancer and Solid Tumors that has completed, run by CanBas Co.. The registered enrollment target is 48 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00551512, a Phase 1 study of Cancer and Solid Tumors, has completed, sponsored by CanBas Co..

COMPLETED
Registry status
Phase 1
Development phase
48 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this research study is to find the answers to the following questions: 1. What are the highest doses of CBP501 and cisplatin that can be safely administered as consecutive 2-hours and 1-hour infusions every 21 days? 2. What are the side effects of the combination of CBP501 and cisplatin when given as an infusion every 21 days? 3. What amount of CBP501 and cisplatin are found in the blood at certain times after it is given? 4. Are there any substances in your blood or tumor that can tell us about tumor sensitivity to CBP501 and cisplatin? 5. Will CBP501 given with cisplatin help to treat your cancer?

Conditions Studied

Interventions

  • DRUG CBP501 and Cisplatin

Study Locations (3)

Arizona

  • Scottsdale Clinical Research Institute - Scottsdale

Massachusetts

  • Dana Farber Cancer Institute - Boston

Nevada

  • Nevada Cancer Institute - Las Vegas

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2006-11
Est. Completion 2009-05
Phase Phase 1

Sponsor

CanBas Co.

5 total trials

What the Registry Record Tells You About NCT00551512

The ClinicalTrials.gov registry entry for NCT00551512 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The listed sponsor is CanBas Co., which has 5 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which CBP501 and Cisplatin is the first listed.

NCT00551512 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Massachusetts, Nevada.

Frequently Asked Questions

What is clinical trial NCT00551512 about?

NCT00551512 is a clinical study titled "Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors". The purpose of this research study is to find the answers to the following questions: 1. What are the highest doses of CBP501 and cisplatin that can be safely administered as consecutive 2-hours and 1-hour infusions every 21 days? 2. What are the side effects of the combination of CBP501 and cispla...

What is the current status of trial NCT00551512?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2006-11. Estimated completion is 2009-05.

What conditions does trial NCT00551512 study?

This clinical trial studies the following conditions: Cancer, Solid Tumors.

What interventions are being tested in trial NCT00551512?

The interventions under investigation include: CBP501 and Cisplatin (DRUG).

Who is sponsoring clinical trial NCT00551512?

This trial is sponsored by CanBas Co., which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00551512 being conducted?

This trial has 3 study locations across Arizona, Massachusetts, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.